Literature DB >> 15854925

Surgical treatment of ascending aortic aneurysms in patients with giant cell aortitis.

Kenton J Zehr1, Alok Mathur, Thomas A Orszulak, Charles J Mullany, Hartzell V Schaff.   

Abstract

BACKGROUND: Giant cell aortitis is a rare cause of ascending aortic aneurysm disease despite giant cell arteritis being a common cause of vasculitis. We evaluated an 8-year experience with surgical repair with regard to preoperative variables, extent of disease, required surgical procedures, and the propensity to develop additional great vessel aneurysms.
METHODS: Thirty-seven patients (29 female, 8 male; aged 69.6 +/- 9.5 years) were operated on from 1995 to 2002. Ten (27%) patients had a history of steroid treatment for temporal arteritis or polymyalgia rheumatica 8.9 +/- 3.9 years before. Nineteen (51%) patients had +3 or +4 aortic regurgitation. Maximal aneurysm size was 6.1 +/- 0.8 cm. Thirty (81%) patients underwent polyethylene terephthalate fiber (Dacron) tube graft replacement of the ascending aorta, 4 (11%) had a modified Bentall procedure, 2 (5%) had a valve-sparing aortic root reconstruction, and 1 (3%) had aortorrhaphy. Twenty-two (59%) patients required 22 +/- 9 minutes of hypothermic circulatory arrest for hemiarch or complete aortic arch replacement. Twenty-six (70%) patients had concomitant cardiac procedures.
RESULTS: There was no early mortality. Morbidity was reexploration for bleeding in 3 (8%) patients, stroke in 3 (8%), left vocal cord paralysis in 2 (5%), renal failure in 2 (5%), and gastrointestinal bleeding in 1 (3%). Mean follow-up was 2.8 +/- 2.3 years. Four-year actuarial survival was 74% (95% confidence interval, 57% to 94%). Other descending or abdominal aortic or great vessel aneurysms occurred in 17 (46%) patients. Four patients had prior aneurysm surgery, 8 are monitored with aneurysms, and 5 underwent repair of an aneurysm in the follow-up period. Of 8 late deaths, 3 were caused by complications of a descending thoracic aneurysm. No patient required replacement of a native aortic valve that was preserved during the initial operative procedure.
CONCLUSIONS: Ascending aortic aneurysms caused by giant cell aortitis can involve the aorta from the aortic root through the aortic arch, thus requiring a tailored operative approach. The aortic valve tissue is spared from the pathologic process. Other aneurysms of the aorta and great vessels occur in nearly half of patients. Frequent surveillance of the remaining aorta is mandatory.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15854925     DOI: 10.1016/j.athoracsur.2004.10.039

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  9 in total

Review 1.  Aortitis.

Authors:  Heather L Gornik; Mark A Creager
Journal:  Circulation       Date:  2008-06-10       Impact factor: 29.690

2.  Modified reduction aortoplasty with external reinforcement of the ascending aortic aneurysm caused by giant cell arteritis treated as polymyalgia rheumatica.

Authors:  Jun Hirota; Syunichi Kondo; Tsuyoshi Yamabe; Taichi Kondo; Yuki Seto; Shigebumi Suzuki
Journal:  Gen Thorac Cardiovasc Surg       Date:  2012-08-15

3.  Combined medical, surgical and endovascular treatment of a giant cell arteritis case manifesting as upper limbs acute ischemia.

Authors:  Stefano de Franciscis; Giuseppe Roscitano; Raffaele Serra; Gianluca Buffone; Attilio Cotroneo; Andrea de Franciscis; Diego Mastrangelo; Francesco Spinelli
Journal:  Int J Surg Case Rep       Date:  2011-02-15

Review 4.  [Large vessel vasculitis].

Authors:  L Caspary; S Schellong
Journal:  Internist (Berl)       Date:  2009-08       Impact factor: 0.743

5.  Current diagnosis and treatment of temporal arteritis.

Authors:  Wolfgang A Schmidt
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-04

6.  Thoracic aortic aneurysms due to giant cell aortitis.

Authors:  Muhammad A Cheema; David H MacIver
Journal:  J R Soc Med       Date:  2016-06       Impact factor: 5.344

7.  Refractory PMR with aortitis: life-saving treatment with anti-IL6 monoclonal antibody (tocilizumab) and surgical reconstruction of the ascending aorta.

Authors:  Fahd Adeeb Mohamed Ashraf; Shakeel Anjum; Abid Hussaini; Alexander Fraser
Journal:  BMJ Case Rep       Date:  2013-06-18

8.  Insights into imaging of aortitis.

Authors:  Diana E Litmanovich; Afra Yıldırım; Alexander A Bankier
Journal:  Insights Imaging       Date:  2012-09-20

9.  Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis.

Authors:  Sara Monti; Ana F Águeda; Raashid Ahmed Luqmani; Frank Buttgereit; Maria Cid; Christian Dejaco; Alfred Mahr; Cristina Ponte; Carlo Salvarani; Wolfgang Schmidt; Bernhard Hellmich
Journal:  RMD Open       Date:  2019-09-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.